title: Facilitated skin permeation of oregonin by elastic liposomal formulations and suppression of atopic dermatitis in NC/Nga mice.
abstract: To develop an external preparation of oregonin (ORG) for the treatment of atopic dermatitis (AD), conventional creams (CC) and elastic liposomes (EL) containing ORG have been formulated and examined for their in vitro skin permeation properties and in vivo therapeutic efficacy assessments. EL, consisting of soybean phosphatidylcholine and Tween 80 (85 : 15 w/w %), were of flexible nanocarriers: they were about 130 nm in size and had a 4-fold greater deformability index than conventional liposomes. In a skin permeation study using a Franz diffusion cell mounted with depilated mouse skin, liposomal systems were superior to cream, revealing greater flux values. Both CC and EL were diversified with the addition of Trans-activating transcriptional activator (Tat) peptide, a sort of cell penetrating peptide, and subjected to in vivo efficacy evaluations in NC/Nga mice with AD-like lesions. On clinical observation for skin severity, rapid and profound improvement was observed in the treatment group with Tat-added liposomes (EL/T), showing a significant difference (p<0.05) versus Tat-added cream. The results indicated that EL/T treatment is effective for normalizing the immune-related responses and alleviating AD, evaluated as changes in the levels of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), interleukin (IL)-4, immunoglobulin E (IgE), and eosinophils in skin or blood.
authors.affiliation: Division of Pharmaceutical Sciences, College of Pharmacy, Chung-Ang University, Seoul, Korea.
authors.forename: Myung Joo
authors.initials: MJ
authors.lastname: Kang
authors.forename: Jae Yoon
authors.initials: JY
authors.lastname: Eum
authors.forename: Mi Sook
authors.initials: MS
authors.lastname: Jeong
authors.forename: Sun Eun
authors.initials: SE
authors.lastname: Choi
authors.forename: Sang Han
authors.initials: SH
authors.lastname: Park
authors.forename: Hye In
authors.initials: HI
authors.lastname: Cho
authors.forename: Chin Sung
authors.initials: CS
authors.lastname: Cho
authors.forename: Seong Jun
authors.initials: SJ
authors.lastname: Seo
authors.forename: Min Won
authors.initials: MW
authors.lastname: Lee
authors.forename: Young Wook
authors.initials: YW
authors.lastname: Choi
mesh_terms: D000287:Administration, Topical; D029661:Alnus / Q000737:chemistry*; D000818:Animals; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D036381:Diarylheptanoids / Q000494:pharmacology / Q000627:therapeutic use*; D004304:Dosage Forms; D004548:Elasticity; D005260:Female; D007107:Immune System / Q000187:drug effects; D008081:Liposomes; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D049329:Nanostructures; D010539:Permeability / Q000187:drug effects; D010713:Phosphatidylcholines; D008517:Phytotherapy; D010936:Plant Extracts / Q000494:pharmacology / Q000627:therapeutic use*; D011136:Polysorbates; D012720:Severity of Illness Index; D012867:Skin / Q000187:drug effects*; D013025:Glycine max / Q000737:chemistry; D015534:Trans-Activators / Q000494:pharmacology
chemical_list: D003879:Dermatologic Agents; D036381:Diarylheptanoids; D004304:Dosage Forms; D008081:Liposomes; D010713:Phosphatidylcholines; D010936:Plant Extracts; D011136:Polysorbates; D015534:Trans-Activators; C409456:oregonin